Bioheart, Inc.Bioheart, Inc. is focused on the discovery, development and commercialization of cell-based therapy products for the treatment of cardiovascular diseases such as congestive heart failure (“CHF”) secondary to myocardial infarction (“MI”) and cardiovascular electrical abnormalities. The Company believes that its products hold the potential to revolutionize the treatment of cardiovascular diseases and become a new standard of care by offering treatments that improve cardiac function, are more cost-effective and are lower-risk than the current alternatives, which include heart transplantation, biventricular pacing, ventricular assist devices and certain drug therapies.
Bioheart’s initial patient-derived (“autologous”) cellular-based implant technology (MyoCell™) harvests specially selected cells from a patient’s own thigh muscle and utilizes that raw material to produce uniquely composed implants that are placed into the heart either percutaneously (via cardiac catheter) or surgically. The MyoCell therapy is designed to regenerate infarcted, scarred or non-functioning myocardial tissue into functioning muscle that contributes to increased global cardiac output and slows down the progression of CHF. The MyoCell product has also demonstrated the ability to positively impact the heart muscle remodeling process. It is expected that the market for MyoCell will include anyone who has suffered from a heart attack (myocardial infarction).
Bioheart believes it is uniquely positioned as the only company in the regenerative cardiac space (or “cardiac cell therapy space”) that can deliver its product to the affected area utilizing a minimally invasive catheter system. Bioheart’s competitors are using an open heart surgical procedure requiring direct myocardial injection.